How much funding has Thrive Earlier Detection raised?

Thrive Earlier Detection has raised $367.0M in total funding, most recently a Series B round.

Who are Thrive Earlier Detection's investors?

Thrive Earlier Detection's investors include Casdin Capital, Section 32, Third Rock Ventures, Bain Capital Life Sciences, Brown Advisory, Driehaus Capital Management.

When was Thrive Earlier Detection founded?

Thrive Earlier Detection was founded in 2019.

Where is Thrive Earlier Detection headquartered?

Thrive Earlier Detection is headquartered in Cambridge, Maryland, United States.

What industry is Thrive Earlier Detection in?

Thrive Earlier Detection operates in Biotech, Diagnostics, Oncology.

How many employees does Thrive Earlier Detection have?

Thrive Earlier Detection has 51-200 employees.

Thrive Earlier Detection

Closed

Cambridge, United States · Founded 2019 · $367.0M raised

Biotech

Diagnostics

Oncology

Headquarters: Cambridge, Maryland
Employees: 51–200
Founded: 2019
Business Model: B2B

Total Funding: $367.0M
Last Round: $257.0M Series BJul 2020
Rounds: 2

About

Thrive Earlier Detection was a Cambridge, Maryland-based liquid biopsy company commercializing CancerSEEK, a multi-cancer early detection blood test developed by Johns Hopkins researchers Bert Vogelstein, Ken Kinzler, and Nickolas Papadopoulos. Founded in 2019 with a $110M Series A, Thrive received FDA Breakthrough Device designation for detecting pancreatic and ovarian cancers. The company raised $257M in additional funding before being acquired by Exact Sciences in October 2020 for $2.15 billion.

Summary

Thrive Earlier Detection is a Biotech company based in Cambridge, United States, founded in 2019. It has raised $367.0M in total across 2 rounds, most recently a $257.0M Series B round in Jul 2020. Investors include Casdin Capital, Section 32 and Third Rock Ventures.